drugset
drugset / Trial / NCT00938366

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

NCT00938366 ↗

Phase 1 Completed 18 enrolled Merck KGaA, Darmstadt, Germany Merck Serono S.A., Geneva · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the stability of cladribine and thereby its bioavailability

Timeline

Start
2008-01
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cladribine Small molecule 10 mg Oral
Subject Pantoprazole Other / unclassified 40 mg Oral

Indications

multiple sclerosis